Afatinib, an EGFR/Her-2 dual inhibitor, effectively radiosensitizes bladder cancer cells

被引：0
|
作者：
Tsai, Yu-Chieh [1 ]
Chen, Jason Chia-Hsien [1 ]
Tuan, Tsung-Fan [1 ]
Yeh, Chih-Hsien [1 ]
Ho, Pei-Yin [2 ]
Pu, Yeong-Shiau [1 ]
Cheng, Ann-Lii [1 ]
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Natl Taiwan Univ, Taipei 10764, Taiwan
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-1464
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1464
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Anti-tumor effect of afatinib, an irreversible EGFR/HER2 dual inhibitor, in lung cancers harboring HER2 oncogene
    Suzawa, Ken
    Toyooka, Shinichi
    Sakaguchi, Masakiyo
    Ohtsuka, Tomoaki
    Watanabe, Mototsugu
    Hashida, Shinsuke
    Maki, Yuho
    Yamamoto, Hiromasa
    Soh, Junichi
    Asano, Hiroaki
    Tsukuda, Kazunori
    Miyoshi, Shinichiro
    CANCER RESEARCH, 2015, 75
  • [22] Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo
    Mu, Yi
    Sun, Deyu
    MEDICAL SCIENCE MONITOR, 2018, 24 : 5811 - 5819
  • [23] Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2
    Wu, Yifen
    Li, Rong
    Zhang, Junyi
    Wang, Gang
    Liu, Bin
    Huang, Xiaofang
    Zhang, Tao
    Luo, Rongcheng
    ONCOTARGETS AND THERAPY, 2015, 8 : 2577 - 2587
  • [24] Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
    Konecny, G. E.
    Venkatesan, N.
    Yang, G.
    Dering, J.
    Ginther, C.
    Finn, R.
    Rahmeh, M.
    Fejzo, M. Schoenberg
    Toft, D.
    Jiang, S-W
    Slamon, D. J.
    Podratz, K. C.
    BRITISH JOURNAL OF CANCER, 2008, 98 (06) : 1076 - 1084
  • [25] Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
    G E Konecny
    N Venkatesan
    G Yang
    J Dering
    C Ginther
    R Finn
    M Rahmeh
    M Schoenberg Fejzo
    D Toft
    S-W Jiang
    D J Slamon
    K C Podratz
    British Journal of Cancer, 2008, 98 : 1076 - 1084
  • [26] Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
    Harada, Yohei
    Sato, Akemi
    Nakamura, Hideaki
    Kai, Keita
    Kitamura, Sho
    Nakamura, Tomomi
    Kurihara, Yuki
    Ikeda, Sadakatsu
    Sueoka, Eisaburo
    Kimura, Shinya
    Sueoka-Aragane, Naoko
    BMC CANCER, 2023, 23 (01)
  • [27] Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
    Yohei Harada
    Akemi Sato
    Hideaki Nakamura
    Keita Kai
    Sho Kitamura
    Tomomi Nakamura
    Yuki Kurihara
    Sadakatsu Ikeda
    Eisaburo Sueoka
    Shinya Kimura
    Naoko Sueoka-Aragane
    BMC Cancer, 23
  • [28] A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
    Whang, Young E.
    Armstrong, Andrew J.
    Rathmell, W. Kimryn
    Godley, Paul A.
    Kim, William Y.
    Pruthi, Raj S.
    Wallen, Eric M.
    Crane, Jeffrey M.
    Moore, Dominic T.
    Grigson, Gayle
    Morris, Karla
    Watkins, Catharine P.
    George, Daniel J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (01) : 82 - 86
  • [29] EGFR activity in HER-2 over-expressing metastatic breast cancer:: Evidence for simultaneous phosphorylation of Her-2/neu and EGFR
    Gschwantler-Kaulich, D
    Hudelist, G
    Koestler, WJ
    Czerwenka, K
    Mueller, R
    Helmy, S
    Ruecklinger, E
    Kubista, E
    Singer, CF
    ONCOLOGY REPORTS, 2005, 14 (02) : 305 - 311
  • [30] EGFR, HER-2 and COX-2 levels in colorectal cancer
    Antonacopoulou, A. G.
    Tsamandas, A. C.
    Petsas, T.
    Liava, A.
    Scopa, C. D.
    Papavassiliou, A. G.
    Kalofonos, H. P.
    HISTOPATHOLOGY, 2008, 53 (06) : 698 - 706
12345